BIBLIOGRAPHY

205

BIBLIOGRAPHY [1]. Rajan. K.Verma and Sanjay Garg, Current status of drug delivery Techonologies

and

Future

Directions,

Pharmaceutical

Techonology on –line 2001,25(2),1-14. [2]. Yie. W. Chien. Novel Drug Delivery Systems, Revised and expanded, Informa health care, volume 50, 2nd edition, 2011, 139-141& 748-750. [3]. Milo Gibaldi. Biopharmaceutics and clinical pharmacokinetics, Pharmamed press, 4th edition, 2011, 26-28. [4]. N.K. Jain. Advances in Controlled and Novel Drug Delivery, CBS publishers, 2000, 290. [5]. Loyd V.Allen.Jr, Nicholas G.Popvich, Howard C.Ansel. Ansel’s pharmaceutical dosage forms and drug delivery systems, 8th edition, 260-263. [6]. Alford N Martin, Patrick J. Sinko. Martin’s Physical pharmacy and pharmaceutical sciences, 2006, 636-645. [7]. L.Lachman, HA Lieberman, Joseph L Kanig.

The theory and

practice of industrial pharmacy, Verghesh publishing house, 3rd edition, 1990,346. [8]. Joseph R. Robinson, Vincent H.L. Lee. Controlled Drug Delivery Fundamentals and Applications, Second edition, Revised and expanded, 374-376. [9]. Bio Impacts 2012, 2(4),1-10. [10]. Remington, The Science and Practice of Pharmacy, Lippin cott Williams and Wilkins, 20th edition, 2002, 903-914. [11]. ME Aulton. “Pharmaceutics”, the science of dosage form design, Churchill Livingstone, 2nd edition, 2005, 1-5. [12]. Sayed I. Abdel-rehman, Gamal MM, EI-Badry M, preparation and comparative evaluation of sustained release metoclopramide HCl matrix tablets, Saudi Pharmaceutical Journal, 2009, 17,283-288. [13]. Chandran S, Laila FA and Mantha N, Design and evaluation of ethyl cellulose based matrix tablets of Ibuprofen with pH

206

modulated release kinetics, Indian Journal of Pharmaceutical Sciences, September – October 2008. [14]. Gothi GD, Parinh BN, Patel TD, Prajapati ST, Patel DM, Patel CN, Study on Design and Development Of Sustained Release Tablets of Metoprolol Succinate, Journal of Global Pharma Technology, 2010,2(2),69-74. [15]. Basak SC, Reddy JBM, and Lucas Mani KP, Formulation and release behavior of sustained release ambroxol hydrochloride HPMC Matrix tablet, Indian Journal of Pharmaceutical Sciences, 2006,68(5),594-598. [16]. Varshosaz J, Tavakoli N and Kheirolahi, Use of hydrophilic natural gums in formulation of sustained release Matrix tablets of Tramadol hydrochloride AAPS Pharm Sci Tch, 2006; 7(1),E24. [17]. Raghvendra Rao NG, Gandhi S, and Patel T, Formulation and evaluation

of

hydrochloride,

sustained International

release

tablets

Journal

of

of

Tramadol

Pharmacy

and

Pharmaceutical Sciences, 2009, 1(1), 60-70. [18]. DR.Umesh.D,Shihare,Nandkishor.D.Adhao,DR.Kishore.P.Bhusari ,DR.Vijay.B.Mathur,

MR.Digvijay

U.Ambulkar,

Formulation

Development, Ealuation and Validation of Sustained Release Tablets of Aceclofenac,International Journal of Pharmacy and Pharmaceutical Sciences, 2009, 1(2),74 - 80. [19]. Vyas SP, Khar RK. Controlled Drug Delivery. Concepts and advances, 1st edition. Vallabh Prakashan, 2002, 156-189. [20]. N.Murugesh. A concise text book of pharmacology, 5th edition, Sathya publishers, 2000. [21]. Roger Walker. Clinical pharmacy and therapeutics, Churchill livingstone Elsevier, 5th edition, 2012, 753-759. [22]. KD.Tripathi.

Essentials

of

Medical

Pharmacology,

Jaypee

Brothers Medical Publishers, 6th edition, 2008,136 & 294-295. [23]. Laurence brunton, Bruce Chabner, Bjornknollman. Good man & Gilman’s the Pharmacological Basis of Therapeutics, McGrawHill, 12th edition, 2011, 304-308.

207

[24]. Latchaw RE, Alberts MJ, Lev MH, Connors JJ, Harbaugh RE, Higashida RT, Recommendations for imaging of acute ischemic stroke:

a

scientific

statement

from

the

American

Heart

Association. Stroke. 2009, 40, 3646-3678. [25]. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr: American Heart Association Stroke Council, Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009, 40, 2945-2948. [26]. Chung CS, Caplan LR. Stroke and other neurovascular disorders. In: Goetz, CG, eds. Textbook of Clinical Neurology. 3rd ed. Philadelphia, Pa: Saunders Elsevier; 2007, chapter 45. [27]. Lang AE. When and how should treatment be started in Parkinson disease, Neurology. 2009, 72(7 Suppl), S39-43. [28]. Weaver FM, Follett K, Stern M, Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009, 301(1), 6373. [29]. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer's disease: a randomized controlled trial. JAMA. 2008, 300, 1774-1783. [30]. DeKosky ST, Kaufer DI, Hamilton RL, Wolk DA, Lopez OL. The dementias. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. Bradley: Neurology in Clinical Practice. 5th ed. Philadelphia, Pa: Butterworth-Heinemann Elsevier; 2008, chapter 70. [31]. Mayeux R. Early Alzheimer's disease. N Engl J Med. 2010 Jun 10, 362(4), 2194-2201. [32]. Qaseem A, American College of Physicians/American Academy of Family Physicians Panel on Dementia. Current pharmacologic treatment of dementia: a clinical practice guideline from the

208

American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008 Mar 4, 148(5), 370-378. [33]. Sritharan seetharaman and Narayanaan Nallaperumal once daily Alfuzosin hydrochloride extended release tablet: comparison between three layer tablet and single layer tablet, Journal of Innovative Trends in Pharmaceutical Sciences 20011, vol2 (5), 149-159. [34]. Monzurul Amin Roni, Golam Kibria, Reza-ul Jalil in-vitro studies of controlled release Alfuzosin matrix tablets prepared with ethylcellulose

and

hydroxylpropylmethyl

cellulose,

Iranian

journal of Pharmaceutical Sciences, Spring 2009,5(2), 59-68. [35]. Madhu E Nicholas, Karunakar R,Raghunadha Gupta C and Pavan Kumar K, development and evaluation of extended release matrix tablets of Alfuzosin hydrochloride and its comparison with marketed product, Journal of Pharmacy Research, 2011, 4(5), 1436-1437. [36]. Quan Liu, Reeza Fassihi, zero-order delivery of a highly soluble, low dose drug Alfuzosin hydrochloride via gastro - retentive system, International Journal of Pharmaceutics -9668, 2007, No of pages 08 [37]. Anroop nair, Sutrave Vasanti, Racha Gupta, in-vitro controlled release of Alfuzosin hydrochloride using HPMC based matrix tablets

and

pharmaceutical

its

comparison

development

and

with

marketed

technology,

product,

2007,

12(6),

621-625. [38]. Utpal Kumar Sanki,Badal Kumar Mandal, in vitro-in vivo correlation evaluation of generic Alfuzosin modified release tablets, International Scholarly Research Network,2012, 14. [39]. Akhilesh Chandra, Channabasavaraj K.P, Manohara Y.N and Ankita S Mehta, spectrophotometric methods for Quantitative estimation of Alfuzosin hydrochloride in bulk and pharmaceutical preparations Indian Journal of Pharmaceutical Education and Research 2008,42(4),323 – 325.

209

[40]. Adsule Prajakta V,Miniyar Anand S, Choudhari Ganesh B, Choudhari Vishnu P, Kuchekar Bhanudas S, development and validation of UV spectrophotometric methods for estimation of Alfuzosin in bulk and pharmaceutical formulation, International Journal of Pharmaceutical Research and Development, 2011, 3(11), 195-199. [41]. Safwan

Ashour,

M.Fawaz

Chehna,Roula

Bayram,

spectrophotometric determination of alfuzosin hydrochloride in pharmaceutical formulations with some sulphonephthalein dyes, International Journl of Biomedical Sciences,

2006, 2(3), 273-

278. [42]. M.Vamsi

Krishna

and

D.Gowri

Sankar,

optimization

and

validation of quantitative spectrophotometric methods for the determination of Alfuzosin in Pharmaceutical Formulations, EJournal of Chemistry, 2007, 4(3), 397-407. [43]. Dipti B Patel,Natubhai J Patel, development and validation of reverse phase high performance liquid chromatography and high performance thin layer chromatography methods for estimation of

Alfuzosin

hydrochloride

in

bulk

and

pharmaceutical

formulations, international journal of chem. Tech research, 2009, 1(4), 985-990. [44]. K.S.Bharathkumar, V.AshaRanjaniand D.Sathyavathi, new RPHPLC method development and validation for assay of Alfuzosin hydrochloride in tablet dosage form, International of Pharmacy and Pharmaceutical Sciences,2010, 2(4), 90-92. [45]. Mani

Ganesh,

Satish

Uppatyay,

Rishi

Tivari,

Thangavel

Sivakumar, Govindasamy Rathinavel, Swastika Gangully and Kaliappan hydrochloride

Kamalakannan, in

quantitation

pharmaceutical

formulation

of by

Alfuzosin RP-HPLC,

Pakistan Journal of Pharmaceutical Sciences, 2009, 22(3), 263266. [46]. Vandana P. Patil, Subhash J. Devdhe, Suwarna H. Kale, Vijay J. Nagmoti, Mahesh T. Gaikwad, Sadan and D. Kurhade, Yuvraj R.

210

Girbane, development and validation of new RP-HPLC method for the estimation of Alfuzosin hydrochloride in bulk and tablet dosage form, American Journal of Analytical Chemistry, 2013, 4, 34-43. [47]. Utpal Kumar Sanki, Badal Kumar Mandal, in vitro-in vivo correlation evaluation of generic Alfuzosin modified release tablets, International Scholarly Research Network, 2012, No of Pages 14. [48]. Madhura V. Dhoka, Rupali B. Harale, Sanjay J. Kshirsagar, Sonal C. Bhankele, Mrinalini C. Damle and Omkar S. Vidwans, development, validation and comparative statistical evaluation of HPLC and HPTLC method for determination of Alfuzosin in human

plasma,

Journal

of

Chemical

and

Pharmaceutical

Research, 2012, 4(6), 3207-3214. [49]. Katarzyna Swiader,Maria zun,Piotr Belniak,Mariusz Swiader, Aleksandra Szopa, Regina Kasperek, Ewa Poleszak, the release of sodium citicoline from enteric coated tablets, annals universitatis mariae curie-sklodowska,2011, XXIV, N2, 24,191-196. [50]. Amol

R.

Jipkate,

Chandrakant

G.Bonde,

R.

T.

Jadhav,

formulation and evaluation of citicoline sustained Release Tablet, Journal of Pharmaceutical Sciences and Research, 2011, 3(1), 911-917. [51]. Neetu Sachan, Phool Chandra, Mayank Yadav, Dilipkumar Pal and Ashoke K Ghosh, rapid analytical procedure for citicoline in bulk and pharmaceutical dosage form by UV Spectrophotometer, Journal of Applied Pharmaceutical Science,2011,01(06),191-193. [52]. Sagar Suman Panda, Ganeswar Mohanta, Bera Venkata Varaha Ravikumar, difference

estimation

of

citicoline sodium

spectrophotometric

method,

in

chronicles

tablets by of

young

scientists, 2013,4(1),18-20. [53]. Malipatil S.M,Patil S.K, Deepti.M and Kishwar Jahan, new spectrophotometric methods for the determination of citicoline in pharmaceutical formulations, IJPRD, 2010, 2(8), 27-30.

211

[54]. Raveendra babu G., Sri Madhu Sri M, M. Prasada Rao, CH. Ajay babu, P. Jayachandra reddy and D. Nagaraju, a validated, specific stability –indicating RP-LC method for citicoline and its related substances in oral drops, International Journal of Pharmacy and Technology,2010,2(3), 651-660. [55]. Sonali O. Uttarwar, R.T. Jadhav, C.G. Bonde, stability indicating LC method for citicoline sustained release tablet, International Journal of Pharm Tech Research, 2010, 2(4), 2482-2486. [56]. K.Tulasi, M.Mathrusri Annapurna, M.Siri Chandra and B.Swathi, high

performance

determination

of

liquid

chromatographic

citicoline

sodium,3rd

method

world

for

congress

the on

bioavailability & Bioequivalence, 2012, 4(3), 189. [57]. Raveendra

B.Ganduri,

Jayachandra

R.Peddareddigari,

Ravi

K.Saiempu and Naga R.Dasari, stability indicating LC method for the determination of citicoline sodium in injection formulation, International Journal

of Pharmtech

Research,

2010,

2(1),

427 – 433. [58]. Sanjay Surani, Prachi Kabra, Ritu Kimbahune and Urmila G.H, spectrophotometric determination of citicoline sodium in pure form and pharmaceutical formulations, Der Pharmacia letter, 2010, 2(5), 353-357. [59]. Keguang Chen, Chunmin Wei,Rui Zhang,Rong Li,RuichenGuo, Xiaoyan Liu, Guiyan Yuan and Benjie Wang, determination of uridine in human plasma by HPLC and its Application in citicoline sodium Pharmacokinetics and bioequivalence studies, 2011, bioequivalence & bioavailability, 2011, 3(4), 72-76. [60]. Amlan Kanti Sarkar, Debotri Ghosh, Dhiman Haldar, Pradipta Sarkar, Bhaswati Gupta, Sujata Ghosh Dastidar, Tapan Kumar Pal, D, a rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Applicationto in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers, Journal of Pharmaceutical and Biomedical Analysis.

212

[61]. Maryadele J.O’Neil, Patricia E.Heckelman, Cherie B.Koch, Kristin J.Roman, the Merck Index, Merck research laboratories,2006,44. [62]. The

United

States

pharmacopeia/The

National

formulary,

USP35-NF30, Alfuzosin Hydrochloride, 2012, 2097- 2098. [63]. Physician’s desk reference, 64th edition, PDR network, 2010, 3050-3053. [64]. Maryadele J. O’Neil, Patricia E.Heckelman, Cherie B.Koch, Kristin J.Roman, the Merck Index,14th edition, Merck research laboratories, 2006, 388. [65]. Richard

Conant,

Mac,

CN,

and

Alexander

G.Schauss,

Therapeutic applications of citicoline dysfunction in the elderly, alternative medicine review, 2004, 9(1), 17-31. [66]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of pharmaceutical excipients, 5th edition, pharmaceutical press, 2006, 315-317. [67]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of pharmaceutical excipients, 5th edition, pharmaceutical press, 2006, 336-340. [68]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of pharmaceutical excipients, 5th edition, pharmaceutical press, 2006, 346-349. [69]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of pharmaceutical excipients, 5th edition, pharmaceutical press, 2006, 611-616. [70]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of

pharmaceutical excipients, 5th edition, pharmaceutical

press, 2006, 731-733. [71]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of Pharmaceutical excipients, 5th edition, pharmaceutical press, 2006,133- 135. [72]. Raymond C Rowe, Paul J Sheskey and SianC Owen.K, Hand book of Pharmaceutical excipients, 5th edition, pharmaceutical press, 2006,188-191.

213

[73]. Raymond C Rowe, Paul J Sheskey and SianC Owen. K, Hand book of Pharmaceutical excipients, 5th edition, pharmaceutical press, 2006, 430-433. [74]. htpp://eudragit.evonik.com/product/eudragit/en/rlpo. [75]. htpp://eudragit.evonik.com/product/eudragit/en/rspo. [76]. ICH Topic Q2B Validation of analytical procedures: Methodology, http://www.fda.gov/cder/guidance/index.htm. [77]. The United states pharmacopeia/The National formulary, USP35NF30, ˂905˃ Uniformity of dosage Units, 2012, 420-422. [78]. The United states pharmacopeia/The National formulary, USP35NF30, ˂616˃Bulk density and tapped density of powders, 2012, 255-258. [79]. The

United

States

pharmacopeia/The

National

formulary,

USP35-NF30, ˂1174˃ Powder flow, 2012, 801-804. [80]. The Indian Pharmacopeia, uniformity of weight of single dose preparation, Indian Pharmacopeia commission, 2007, 182. [81]. The

United

States

pharmacopeia/The

National

formulary,

USP35-NF30, ˂1217˃ Tablet Breaking force, 2012, 868-870. [82]. The United states pharmacopeia/The National formulary, USP35NF30, ˂1216˃ Tablet Friability, 2012, 867-868. [83]. U.S.Department of Health and Human Services, Food and drug Administration, Centre for Drug Evaluation and Research (CDER) Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. CDER, 1997 [84]. Suvakanta Dash, Padala Narasimha Murthy, Lilakanta Nath and Prasanta Chowdhury, kinetic modeling on drug release from controlled drug delivery systems, Acta Poloniae Pharmaceutica – Drug Research, 2010, 67(3), 217 – 223. [85]. Bidah, D. and Vergnaud, J.M., Int. J. Pharm., 58, 215, 1998. [86]. ICH Topic Q1A (R2) Stability Testing of new Drug substances and Products,http://www.emea.europa.eu

214

[87]. U.S.Department of Health and Human Services, Food and drug Administration, Centre for Drug Evaluation and Research (CDER) Guidance for Industry: Bioanalytical Method Validation. 2001. [88]. Kurt H. Bauer, Klaus Lehmann, Hermann P. Osterwald, Gerhart Rothgang, Coated Pharmaceutical Dosage forms, medpharm GmbH scientific Publishers, 1998, 126 – 127.